CytoDyn Requests EUA for Leronlimab to Treat COVID-19 Patients

Vancouver, Wash.-based drugmaker CytoDyn is seeking an Emergency Use Authorization from the FDA for its HIV treatment leronlimab for the treatment of mild-to-moderate COVID-19 patients.

If granted, leronlimab would be the first drug authorized to treat mild-to-moderate COVID-19 patients and only the second COVID-19 treatment authorized overall. Gilead Sciences’ remdesivir is currently the only authorized COVID-19 treatment.

CytoDyn CEO Nader Pourhassan said the company is filing for emergency authorizations in “many different countries,” including the U.S. If no country grants an authorization, the company will conduct a phase 3 trial, he said.